Eiko Lifesciences Ltd

Eiko Lifesciences Ltd announced the allotment of 1,50,000 equity shares following the conversion of an equal number of warrants. The conversion price was ₹55 per share, including a premium of ₹45. The company received ₹61,87,500, representing 75% of the issue price per warrant, from the allottee, Lenus Finvest Private Limited, a promoter. This conversion increases the company's issued, subscribed, and paid-up equity share capital to ₹14,80,08,540, comprising 1,48,00,854 equity shares of ₹10 each. The new shares will rank pari-passu with existing equity shares.

Eiko Lifesciences Ltd has announced its 49th Annual General Meeting (AGM) will be held on Tuesday, September 22, 2026, at 04:00 P.M. (IST) via Video Conferencing/ Other Audio Visual Means (VC/ OAVM). The company has also released its Annual Report for the Financial Year 2025-26, which is available on its website and being sent electronically to shareholders. The report highlights a transformative FY25-26 with consolidated revenue from operations of ₹5,257.14 lakhs and a profit after tax of ₹358.11 lakhs, a significant increase from the previous year. The EBITDA margin improved to 11.19%. The company also made strategic investments in new businesses, including a step into pharmaceutical formulations.

Eiko Lifesciences Ltd has announced its 49th Annual General Meeting (AGM) will be held on Tuesday, September 22, 2026, at 04:00 PM IST via Video Conferencing/Other Audio Visual Means (VC/OAVM). The meeting will cover the adoption of Audited Standalone and Consolidated Financial Statements for the Financial Year 2025-26, the re-appointment of Mr. Bhavesh Dhirajlal Tanna as a Director, and the approval of Mr. Suraj Mahadev Gaikwad as an Independent Director for a five-year term starting August 24, 2026. Additionally, approval for material related party transactions will be sought. The Notice of the AGM and Annual Report are being sent electronically to shareholders with registered email addresses, and a weblink is provided for others.

Eiko Lifesciences Ltd announced that Ms. Hasti Doshi has resigned from her position as Independent Director, effective August 24, 2026. The resignation is due to other career commitments. Ms. Doshi's term was scheduled to end on September 3, 2029. The company has accepted the resignation and will inform the relevant regulatory authorities.

Eiko Lifesciences Ltd has announced the appointment of Mr. Suraj Mahadev Gaikwad as an Additional Director (Independent and Non-Executive). The appointment was approved by the Board of Directors on August 24, 2026. Mr. Gaikwad will hold the office until the ensuing Annual General Meeting, after which he will serve as an Independent Director for a term of 5 years, subject to shareholder approval. He is a Commerce Graduate with over 7 years of experience in accountancy and business management, bringing expertise in financial operations and strategic planning. This appointment is in compliance with SEBI Listing Regulations.

Eiko Lifesciences Ltd held a Board Meeting on August 24, 2026. The board noted the resignation of Ms. Hasti Doshi as Independent Director and approved the appointment of Mr. Suraj Mahadev Gaikwad as Additional Director (Independent and Non-Executive). The board also recommended the re-appointment of Mr. Bhavesh Dhirajlal Tanna as Director. The Annual General Meeting (AGM) for FY 2025-26 is scheduled for September 22, 2026, to be held via Video Conferencing. Mr. Shravan Gupta was appointed as Scrutinizer for e-voting, and M/s Bigshare Services Pvt Ltd. will provide e-voting and video conferencing services.

Eiko Lifesciences Ltd has received communications and recovery proceedings from IDBI Bank Limited concerning an alleged corporate guarantee of ₹58 lakhs issued by its erstwhile entity, Narendra Investments (Delhi) Limited, in 1986. The company disputes the claim, stating it has neither admitted nor acknowledged any liability. Eiko Lifesciences has initiated legal steps and is pursuing all available remedies. Management believes the matter will not have a material financial impact on the company's operations based on current facts and legal position.

Eiko Lifesciences Ltd announced the conversion of 305,000 warrants into equity shares, raising ₹1.25 crore. The conversion involved 130,000 warrants from promoter Bhavesh Dhirajlal Tanna and 175,000 from non-promoter V Square Pharmachem Private Limited. Each warrant was converted at an issue price of ₹55 per share, including a premium of ₹45. This conversion increases the company's issued, subscribed, and paid-up equity share capital to ₹14.65 crore, comprising 1,46,50,854 equity shares of ₹10 each. The newly allotted shares will rank pari-passu with existing equity shares.

Eiko Lifesciences Ltd announced that its Board of Directors, in a meeting held on August 12, 2026, approved and took on record the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were accompanied by a Limited Review Report from the statutory auditors, PSV Jain & Associates. The company has complied with SEBI Listing Regulations and Indian Accounting Standards (Ind AS 34). The review confirmed no material misstatements in the financial statements.

Eiko Lifesciences Ltd has announced a Board of Directors meeting scheduled for August 12, 2026. The primary agenda is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Additionally, the meeting will address any other matters with the chair's permission. The company has also confirmed that the trading window for designated persons remains closed from July 1, 2026, until 48 hours after the financial results are declared.